{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T20:25:33Z","timestamp":1789849533904,"version":"4.0.1"},"reference-count":50,"publisher":"Elsevier BV","issue":"45","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.vaccine.2018.09.055","type":"journal-article","created":{"date-parts":[[2018,10,4]],"date-time":"2018-10-04T09:44:38Z","timestamp":1538646278000},"page":"6640-6649","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Co-delivery of amphipol-conjugated adjuvant with antigen, and adjuvant combinations, enhance immune protection elicited by a membrane protein-based vaccine against a mucosal challenge with Chlamydia"],"prefix":"10.1016","volume":"36","author":[{"given":"Delia F.","family":"Tifrea","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sukumar","family":"Pal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christel","family":"Le Bon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrice","family":"Giusti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Luc","family":"Popot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie J.","family":"Cocco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela","family":"Zoonens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis M.","family":"de la Maza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2018.09.055_b0005","series-title":"Plotkin's vaccines","author":"Plotkin","year":"2018"},{"key":"10.1016\/j.vaccine.2018.09.055_b0010","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.cell.2006.02.015","article-title":"Pathogen recognition and innate immunity","volume":"124","author":"Akira","year":"2006","journal-title":"Cell"},{"key":"10.1016\/j.vaccine.2018.09.055_b0015","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/nri2038","article-title":"Cooperation of toll-like receptor signals in innate immune defence","volume":"7","author":"Trinchieri","year":"2007","journal-title":"Nat Rev Immunol"},{"issue":"Suppl 2","key":"10.1016\/j.vaccine.2018.09.055_b0020","doi-asserted-by":"crossref","first-page":"S89","DOI":"10.1016\/S0264-410X(03)00206-8","article-title":"Mucosal immunisation and adjuvants: a brief overview of recent advances and challenges","volume":"21","author":"Holmgren","year":"2003","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.09.055_b0025","doi-asserted-by":"crossref","first-page":"323","DOI":"10.3390\/vaccines2020323","article-title":"Immune adjuvant effect of molecularly-defined toll-like receptor ligands","volume":"2","author":"Toussi","year":"2014","journal-title":"Vaccines"},{"key":"10.1016\/j.vaccine.2018.09.055_b0030","unstructured":"CDC. Sexually transmitted diseases surveillance 2015. In: Prevention DoS, editor. U.S. Department of Health and Human Services. Atlanta; 2016. p. 1\u2013176."},{"key":"10.1016\/j.vaccine.2018.09.055_b0035","series-title":"Human chlamydial infections","author":"Schachter","year":"1978"},{"key":"10.1016\/j.vaccine.2018.09.055_b0040","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/QCO.0000000000000343","article-title":"Future prospects for new vaccines against sexually transmitted infections","volume":"30","author":"Gottlieb","year":"2017","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.vaccine.2018.09.055_b0045","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1097\/00007435-199207000-00001","article-title":"Pelvic inflammatory disease and fertility. A cohort study of 1844 women with laparoscopically verified disease and 657 control women with normal laparoscopic results","volume":"19","author":"Westrom","year":"1992","journal-title":"Sex Transm Dis"},{"key":"10.1016\/j.vaccine.2018.09.055_b0050","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1080\/00365540110077001","article-title":"Is the increase in notifications of Chlamydia trachomatis infections in Sweden the result of changes in prevalence, sampling frequency or diagnostic methods?","volume":"34","author":"Gotz","year":"2002","journal-title":"Scand J Infect Dis"},{"key":"10.1016\/j.vaccine.2018.09.055_b0055","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1128\/IAI.00881-10","article-title":"Vaccination against Chlamydia genital infection utilizing the murine C. muridarum model","volume":"79","author":"Farris","year":"2011","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2018.09.055_b0060","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/0264-410X(95)80022-6","article-title":"A new computer model for estimating the impact of vaccination protocols and its application to the study of Chlamydia trachomatis genital infections","volume":"13","author":"de la Maza","year":"1995","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.09.055_b0065","doi-asserted-by":"crossref","DOI":"10.1128\/CVI.00543-16","article-title":"Update on Chlamydia trachomatis vaccinology","volume":"24","author":"de la Maza","year":"2017","journal-title":"Clin Vacc Immunol"},{"key":"10.1016\/j.vaccine.2018.09.055_b0070","series-title":"Trachoma: a blinding scourge from the Bronze Age to the twenty-first century","author":"Taylor","year":"2008"},{"issue":"Suppl","key":"10.1016\/j.vaccine.2018.09.055_b0075","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1016\/0002-9394(67)94155-4","article-title":"Trachoma vaccine studies in monkeys","volume":"63","author":"Wang","year":"1967","journal-title":"Am J Ophthalmol."},{"key":"10.1016\/j.vaccine.2018.09.055_b0080","doi-asserted-by":"crossref","first-page":"723","DOI":"10.4269\/ajtmh.1969.18.723","article-title":"Studies on trachoma. VI. Microbiological observations in a field trial in Saudi Arabia of bivalent rachoma vaccine at three dosage levels","volume":"18","author":"Nichols","year":"1969","journal-title":"Am J Trop Med Hyg"},{"issue":"Suppl","key":"10.1016\/j.vaccine.2018.09.055_b0085","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1016\/0002-9394(67)94158-X","article-title":"Field trial of a monovalent and of a bivalent mineral oil adjuvant trachoma vaccine in Taiwan school children","volume":"63","author":"Woolridge","year":"1967","journal-title":"Am J Ophthalmol."},{"key":"10.1016\/j.vaccine.2018.09.055_b0090","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1001\/archopht.1967.00980030343015","article-title":"Experimental inclusion conjunctivitis in man. 3. Keratitis and other complications","volume":"78","author":"Dawson","year":"1967","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.vaccine.2018.09.055_b0095","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1084\/jem.169.3.663","article-title":"Chlamydial disease pathogenesis. Ocular hypersensitivity elicited by a genus-specific 57-kD protein","volume":"169","author":"Morrison","year":"1989","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2018.09.055_b0100","doi-asserted-by":"crossref","first-page":"3879","DOI":"10.1128\/jb.169.9.3879-3885.1987","article-title":"Diversity of Chlamydia trachomatis major outer membrane protein genes","volume":"169","author":"Stephens","year":"1987","journal-title":"J Bacteriol"},{"key":"10.1016\/j.vaccine.2018.09.055_b0105","first-page":"892","article-title":"Phylogenetic analysis of the outer-membrane-protein genes of Chlamydiae, and its implication for vaccine development","volume":"10","author":"Fitch","year":"1993","journal-title":"Mol Biol Evol"},{"key":"10.1016\/j.vaccine.2018.09.055_b0110","doi-asserted-by":"crossref","first-page":"8153","DOI":"10.1128\/IAI.73.12.8153-8160.2005","article-title":"Vaccination with the Chlamydia trachomatis major outer membrane protein can elicit an immune response as protective as that resulting from inoculation with live bacteria","volume":"73","author":"Pal","year":"2005","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2018.09.055_b0115","doi-asserted-by":"crossref","first-page":"5020","DOI":"10.1016\/j.vaccine.2009.05.008","article-title":"Protection against an intranasal challenge by vaccines formulated with native and recombinant preparations of the Chlamydia trachomatis major outer membrane protein","volume":"27","author":"Sun","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.09.055_b0120","doi-asserted-by":"crossref","first-page":"4374","DOI":"10.1128\/IAI.00622-10","article-title":"CD4+ T cells and antibody are required for optimal major outer membrane protein vaccine-induced immunity to Chlamydia muridarum genital infection","volume":"78","author":"Farris","year":"2010","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2018.09.055_b0125","doi-asserted-by":"crossref","first-page":"5201","DOI":"10.4049\/jimmunol.1303392","article-title":"Increased immunoaccessibility of MOMP epitopes in a vaccine formulated with amphipols may account for the very robust protection elicited against a vaginal challenge with Chlamydia muridarum","volume":"192","author":"Tifrea","year":"2014","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2018.09.055_b0130","doi-asserted-by":"crossref","first-page":"15047","DOI":"10.1073\/pnas.93.26.15047","article-title":"Amphipols: polymers that keep membrane proteins soluble in aqueous solutions","volume":"93","author":"Tribet","year":"1996","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2018.09.055_b0135","series-title":"Membrane proteins in aqueous solutions: from detergents to amphipols","author":"Popot","year":"2018"},{"key":"10.1016\/j.vaccine.2018.09.055_b0140","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1038\/nature04596","article-title":"Toll-dependent selection of microbial antigens for presentation by dendritic cells","volume":"440","author":"Blander","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2018.09.055_b0145","doi-asserted-by":"crossref","first-page":"19902","DOI":"10.1073\/pnas.1313152110","article-title":"Nanoparticle conjugation of CpG enhances adjuvancy for cellular immunity and memory recall at low dose","volume":"110","author":"de Titta","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2018.09.055_b0150","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1021\/ja3063293","article-title":"Colocalized delivery of adjuvant and antigen using nanolipoprotein particles enhances the immune response to recombinant antigens","volume":"135","author":"Fischer","year":"2013","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.vaccine.2018.09.055_b0155","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1586\/14760584.2016.1161510","article-title":"Subunit vaccines for the prevention of mucosal infection with Chlamydia trachomatis","volume":"15","author":"Yu","year":"2016","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2018.09.055_b0160","doi-asserted-by":"crossref","first-page":"7536","DOI":"10.4049\/jimmunol.175.11.7536","article-title":"A predominant role for antibody in acquired immunity to chlamydial genital tract reinfection","volume":"175","author":"Morrison","year":"2005","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2018.09.055_b0165","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.clim.2015.06.006","article-title":"Preliminary evidence that the novel host-derived immunostimulant EP67 can act as a mucosal adjuvant","volume":"161","author":"Karuturi","year":"2015","journal-title":"Clin Immunol"},{"key":"10.1016\/j.vaccine.2018.09.055_b0170","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1016\/j.vaccine.2004.08.049","article-title":"Montanide ISA 720 vaccines: quality control of emulsions, stability of formulated antigens, and comparative immunogenicity of vaccine formulations","volume":"23","author":"Miles","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.09.055_b0175","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.addr.2008.12.010","article-title":"The immunogenicity of CpG-antigen conjugates","volume":"61","author":"Wagner","year":"2009","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.vaccine.2018.09.055_b0180","doi-asserted-by":"crossref","first-page":"3751","DOI":"10.1021\/acs.biomac.5b01010","article-title":"Synthesis of a polyhistidine-bearing amphipol and its use for immobilizing membrane proteins","volume":"16","author":"Giusti","year":"2015","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.vaccine.2018.09.055_b0185","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1021\/la052243g","article-title":"Well-defined nanoparticles formed by hydrophobic assembly of a short and polydisperse random terpolymer, amphipol A8\u201335","volume":"22","author":"Gohon","year":"2006","journal-title":"Langmuir"},{"key":"10.1016\/j.vaccine.2018.09.055_b0190","doi-asserted-by":"crossref","first-page":"10392","DOI":"10.1021\/bi7007596","article-title":"Dynamics of membrane protein\/amphipol association studied by Forster resonance energy transfer: implications for in vitro studies of amphipol-stabilized membrane proteins","volume":"46","author":"Zoonens","year":"2007","journal-title":"Biochemistry"},{"key":"10.1016\/j.vaccine.2018.09.055_b0195","doi-asserted-by":"crossref","first-page":"4623","DOI":"10.1016\/j.vaccine.2011.04.065","article-title":"Amphipols stabilize the Chlamydia major outer membrane protein and enhance its protective ability as a vaccine","volume":"29","author":"Tifrea","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.09.055_b0200","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1007\/s00232-014-9655-y","article-title":"Labeling and functionalizing amphipols for biological applications","volume":"247","author":"Le Bon","year":"2014","journal-title":"J Membr Biol."},{"key":"10.1016\/j.vaccine.2018.09.055_b0205","doi-asserted-by":"crossref","first-page":"4681","DOI":"10.1016\/j.vaccine.2012.04.084","article-title":"An agonist of human complement fragment C5a enhances vaccine immunity against Coccidioides infection","volume":"30","author":"Hung","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.09.055_b0210","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.vaccine.2011.11.010","article-title":"The non-toxic and biodegradable adjuvant Montanide ISA 720\/CpG can replace Freund's in a cancer vaccine targeting ED-B \u2013 a prerequisite for clinical development","volume":"30","author":"Huijbers","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.09.055_b0215","doi-asserted-by":"crossref","first-page":"3076","DOI":"10.1016\/j.vaccine.2004.09.040","article-title":"A human phase 1 vaccine clinical trial of the Plasmodium falciparum malaria vaccine candidate apical membrane antigen 1 in Montanide ISA720 adjuvant","volume":"23","author":"Saul","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.09.055_b0220","doi-asserted-by":"crossref","first-page":"4328","DOI":"10.1016\/S0264-410X(01)00111-6","article-title":"A phase I clinical trial of a multi-epitope polypeptide TAB9 combined with Montanide ISA 720 adjuvant in non-HIV-1 infected human volunteers","volume":"19","author":"Toledo","year":"2001","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.09.055_b0225","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1146\/annurev.immunol.20.100301.064842","article-title":"CpG motifs in bacterial DNA and their immune effects","volume":"20","author":"Krieg","year":"2002","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.vaccine.2018.09.055_b0230","doi-asserted-by":"crossref","first-page":"85ra48","DOI":"10.1126\/scitranslmed.3002336","article-title":"MF59 adjuvant enhances diversity and affinity of antibody-mediated immune response to pandemic influenza vaccines","volume":"3","author":"Khurana","year":"2011","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.vaccine.2018.09.055_b0235","doi-asserted-by":"crossref","first-page":"3329","DOI":"10.1128\/JVI.03309-13","article-title":"Toll-like receptor 7\/8 (TLR7\/8) and TLR9 agonists cooperate to enhance HIV-1 envelope antibody responses in rhesus macaques","volume":"88","author":"Moody","year":"2014","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2018.09.055_b0240","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1084\/jem.176.5.1483","article-title":"Adjuvant-dependent immune response to malarial transmission-blocking vaccine candidate antigens","volume":"176","author":"Rawlings","year":"1992","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2018.09.055_b0245","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1128\/iai.61.2.498-503.1993","article-title":"Effects of antibody isotype and host cell type on in vitro neutralization of Chlamydia trachomatis","volume":"61","author":"Peterson","year":"1993","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2018.09.055_b0250","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0010768","article-title":"Protection against Chlamydia promoted by a subunit vaccine (CTH1) compared with a primary intranasal infection in a mouse genital challenge model","volume":"5","author":"Olsen","year":"2010","journal-title":"PLoS ONE"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18313240?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18313240?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:28:46Z","timestamp":1759400926000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X18313240"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":50,"journal-issue":{"issue":"45","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["S0264410X18313240"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.09.055","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Co-delivery of amphipol-conjugated adjuvant with antigen, and adjuvant combinations, enhance immune protection elicited by a membrane protein-based vaccine against a mucosal challenge with Chlamydia","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.09.055","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}